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The cannabinoid receptor 1 (CB1R) is the G-protein coupled receptor responsible for the
majority of the endocannabinoid signaling in the human brain. It is widely distributed in the
limbic system, basal ganglia, and cerebellum, which are areas responsible for cognition,
memory, and motor control. Because of this widespread distribution, it is not surprising
that drugs that activate CB1R have expected behavioral outcomes consistent with dysreg-
ulated signaling from these areas (e.g., memory loss, cognitive deﬁcits, etc). In the context
of this review, we present evidence for the role of CB1R signaling in the prefrontal cortex
(PFC), an area involved in executive functions, with emphasis on the developmental regu-
lation of CB1R signaling in the acquisition of mature PFC function.We further hypothesize
how alterations in CB1R signaling speciﬁcally during adolescent maturation might confer
liability to psychiatric disorders.
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This article reviews the available evidence of long-lasting cognitive
deﬁcits induced by cannabis consumption during adolescence and
its relationship to schizophrenia, and presents a workingmodel for
dissecting the mechanisms involved in this dysfunction based on
the current clinical and preclinical knowledge. Because of the role
of the prefrontal cortex (PFC) in higher cognitive functions, we
have limited our discussion and conclusions to the role of endoge-
nous and exogenous cannabinoid signaling in prefrontal circuits.
Importantly, the machinery involved in cannabinoid signaling is
found in other cortical and subcortical regions (e.g., amygdala,
striatum), which have also been implicated in other aspects of
schizophrenia’s symptomatology and therefore are beyond the
scope of this Perspective Review.
CANNABIS, CORTICAL DEVELOPMENT, AND THE LIABILITY
FOR SCHIZOPHRENIA
Adolescence is the transitional period between childhood and
adulthood that is accompanied by reﬁnement of cognitive func-
tions thought to underlie the acquisition of mature behavior
(Casey et al., 2000; Spear, 2000).Many of these executive functions,
such as problem solving, working memory, abstract thinking, and
increased inhibitory control are processedby thePFC.Accordingly,
the PFC is one of the last brain regions to develop and undergo
changes during late adolescence that include increased myelina-
tion and synaptic pruning (Andersen, 2003; Chambers et al., 2003;
Crews et al., 2007). This active remodeling of brain areas cre-
ates a developmental window where environmental factors can
affect the normal trajectories of cortical circuits. Indeed, cannabis
use during adolescence has been associated with increased lia-
bility of developing neuropsychiatric and abuse disorders later
in life (Arseneault et al., 2002, 2004; Zammit et al., 2002; Caspi
et al., 2005; Moore et al., 2007). Speciﬁcally, there is a concern
that cannabis use/abuse during adolescence results in increased
risk of developing schizophrenia-spectrum disorders in adult-
hood, although the mechanisms underlying such an association
still remain unclear (Sewell et al., 2009). Given that adolescence is
a period of increased liability to drug addiction due to inherent
novelty-seeking (Spear,2000;Chambers et al., 2003), it is of utmost
importance to determine the mechanisms of this impairment for
sensible public policy implementation.
Administration of cannabinoids to otherwise healthy adult
individuals causes psychotic symptoms including paranoia, per-
ceptual alterations, conceptual disorganization, and fragmented
thinking, similar to the positive symptoms experienced by patients
with schizophrenia (D’Souza et al., 2004). Notably, controlled
cannabis administration in patients with schizophrenia exacer-
bates the positive symptoms and increases the cognitive deﬁcits,
suggesting a common underlying mechanism (D’Souza et al.,
2005). In addition, adult subjects administered cannabinoids dis-
play deﬁcits in memory recall, attention, and inhibitory control
(Hart et al., 2001; D’Souza et al., 2004; Henquet et al., 2006).
Although the long-term effects of chronic cannabis use are still
debated, acute cannabinoid administration shows mostly tran-
sient effects in adult individuals, suggesting that only a speciﬁc
dysregulation by cannabinoids during developmentally sensitive
periods like adolescence could be responsible for the long-lasting
deﬁcits seen in prefrontal functioning.
In support of this hypothesis, morphological examination of
brains from cannabis users has demonstrated signiﬁcant smaller
gray matter volumes in cortical regions when cannabis use starts
before the age of 17 (Wilson et al., 2000). Early-onset use of
cannabis also results in attentional dysfunctions reﬂected in
reduced phasic alertness and attention (Ehrenreich et al., 1999).
Moreover, an early vs. late adolescent exposure to cannabis can give
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rise to speciﬁc impairments in visual scanning, a test that assesses
the reaction time to the processing of visual stimuli (Ehrenre-
ich et al., 1999). Pope et al. (2003) have found that early-onset
users (before age 17) show deﬁcits in verbal IQ compared to
late-onset users, and differ signiﬁcantly from control subjects in
other verbal functions involvingmemory and recall.More recently,
Fontes et al. (2011) have established that individuals with early-
adolescence onset of cannabis use (before age 15) score poorer in
prefrontal-lobe related tasks, and signiﬁcantly worse than the late-
adolescent-onset group. All in all, the bulk of evidence seems to
indicate that cannabis use during or evenwithin speciﬁc periods of
adolescence can lead to enduring cognitive impairments involving
the PFC.
The precise neural substrates underlying cannabinoid-induced
cognitive impairments remain elusive; however, evidence sug-
gests that cannabis affects the integration of cortical informa-
tion. In cortical structures, information processing is thought
to be mediated by the synchronization of neuronal networks,
such that spatio-temporal integration of networks functionally
encodes cortical-related behaviors and cognition. This is typi-
cally manifested as changes in cortical oscillations at different
frequency bands and synchrony between different regional net-
works (Buzsaki and Draguhn, 2004). This is especially important
in the light that patients with schizophrenia show abnormal oscil-
lations in the theta (4–7Hz) and gamma range (30–200Hz), and
abnormal synchrony between cortical structures, suggesting aber-
rant integration of large and local neuronal circuits (Spencer et al.,
2003; Uhlhaas and Singer, 2010). Similarly, cannabis smoking
decreases theta oscillations, and this correlates with detrimen-
tal effects on working memory task performance (Ilan et al.,
2004).More recently,D’Souza et al. have determined that cannabis
administration dose-dependently reduces the amplitude of event-
related potentials (ERPs, a measure of network responses to a
stimulus) in an auditory task assessing attention and cognition
(D’Souza et al., 2012). These data indicate that cannabis com-
promises both context updating and allocation of attentional
resources. Similar reductions in ERPs have been observed in
schizophrenia and are associated with decreased shift in atten-
tion (Rissling et al., 2010). Altogether, cannabis disrupts cortical
network dynamics similar to those reported in schizophrenia, sug-
gesting that exogenous cannabinoids can alter the physiology of
brain circuits involved in higher-order cognitive processing.
ENDOCANNABINOIDS AND CB1 RECEPTOR SIGNALING IN
THE CENTRAL NERVOUS SYSTEM
The endocannabinoid system is comprised by the receptors, syn-
thesizing and inactivating enzymes that mediate the actions of
natural endogenous cannabinoids (Kreitzer and Regehr, 2002;
Lovinger, 2008). The cannabinoid receptor 1 (CB1R) is the G-
protein coupled receptor responsible for most endocannabinoid
signaling in the brain (Matsuda et al., 1990). It is widely expressed
in the vertebrate brain, and at especially high levels in the cortex,
hippocampus, cerebellum, and the various nuclei of the basal gan-
glia where its expression is mostly presynaptic (Herkenham et al.,
1991; Pettit et al., 1998; Egertova and Elphick, 2000). Under phys-
iological conditions, CB1R binds the endogenous cannabinoids
anandamide (AEA) and 2-arachydonylglycerol (2-AG). These fatty
acid-derived ligands are produced in the postsynaptic membrane
as a result of neurotransmitter binding to its cognate receptors
(Lovinger, 2008). Endocannabinoids then diffuse in a retrograde
manner and bind to the presynaptically located CB1R.Here,CB1R
signaling is mostly mediated by coupling to pertussis-sensitive
Gi/o proteins which effectively inhibit the enzyme adenylate
cyclase (Vogel et al., 1993) leading to a local reduction of cAMP
levels that decreases PKA activity and leads to activation of A-type
K channels. In addition, CB1R signaling inhibits N- and Q-type
Ca++ currents which are necessary for neurotransmitter release at
the presynaptic site (Lovinger, 2008). Because of this genericmode
of action, endocannabinoid-mediated CB1R signaling is capable
of modulating a broad range of neurotransmitters including glu-
tamate, GABA, dopamine, serotonin, and acetylcholine (Lovinger,
2008). In this sense, the endocannabinoid system has a homeosta-
tic role in controlling excessive excitation or inhibition and acts
continuously through an intrinsic “tone” (Marsicano et al., 2003;
Katona and Freund, 2008).
THE ROLE OF CB1R SIGNALING IN COGNITIVE FUNCTIONS
Interest in CB1R signaling arises from the fact that it is the receptor
responsible for binding the psychoactive components of cannabis,
most prominently Δ9-THC, leading to the behavioral abnormal-
ities associated with marijuana use, including but not limited to
memory retrieval, euphoria, and in rare cases psychosis (Iversen,
2003). Given that cannabis containsmore than 70 known cannabi-
noids (Elsohly and Slade, 2005), synthetic cannabinoids have been
utilized over the years to systematically dissect the role of CB1
receptor in the development and function of the PFC.
Similar to the effect of cannabis in humans, administration
of CB1R agonists in rodents during the adolescent transition to
young adulthood (from PD35 to PD65) can lead to behavioral
impairments in adulthood that model those observed in schiz-
ophrenia. Accordingly, rats chronically treated with the CB1R
agonist WIN55,212-2 (WIN) from PD40 to 65 and tested in
adult (PD75-150) exhibit deﬁcits in sensorimotor gating, short-
term memory, and invest less effort for reward, a proxy for
anhedonia (Schneider and Koch, 2003). WIN-treated rats also
displayed reduced object-social discrimination, social interaction,
and spontaneous social behavior as adults, indicating permanent
deﬁcits in recognition memory and increased anxiety (Schneider
et al., 2008). Similarly, rats treated with the synthetic cannabi-
noid CP55,940 from the juvenile period (PD30) to PD51 also
display reduced object recognition and social interactions dur-
ing adulthood (O’Shea et al., 2004). The residual effects in object
recognition and anxiety have also been observed in adult rats
treated with Δ9-THC from PD32 to 55 (Quinn et al., 2008).
Interestingly, rats treated during adulthood lacked any permanent
deﬁcits on these behavioral measures, suggesting that cannabi-
noids had a signiﬁcant effect only when treatment spanned ado-
lescence (Schneider and Koch, 2003; O’Shea et al., 2004; Bortolato
et al., 2005; Schneider et al., 2008). Notably, a recent study found
that rats administeredWIN from PD45 to 60 exhibited signiﬁcant
long-lasting effects in ahippocampal-dependent task,while amore
PFC-dependent task was impaired only transiently (no impair-
ment after 30 days; Abush and Akirav, 2012). Thus, there seems
to be a differential sensitivity to cannabinoids that is dependent
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on the interaction of the speciﬁc developmental window of CB1R
activation with the speciﬁc ontogeny of brain structures that are
rich in CB1 receptors.
CB1 RECEPTOR EXPRESSION AND SIGNALING IN THE
FRONTAL CORTEX
In considering the role of CB1R in the development of the cen-
tral nervous system, it is well known that CB1R expression plays
an important role during the prenatal and early postnatal period.
During this time, CB1R plays a critical role in neurogenesis, axon
migration, and synaptogenesis (for review Harkany et al., 2007).
Consistent with these ﬁndings, CB1R expression appears as early
as gestational day (GD) 14 and by GD16 is clearly expressed
across the developing frontal cortex, hippocampus, striatum, and
midbrain (Berrendero et al., 1998). Another study determined
that CB1R binding can be detected at different levels by PD10
and increases steadily until adolescence in several limbic regions,
including the frontal cortex, striatum, and mesencephalon, after
which binding starts declining (Rodriguez de Fonseca et al., 1993).
In addition, we have recently demonstrated that CB1R mRNA
expression drops in all cortical areas during the adolescent tran-
sition to adulthood, most prominently in the limbic/associative
cortex (prelimbic, infralimbic, and cingulate). More importantly,
this decrease of CB1R expression is associated with a functional
decline in CB1R-mediated signaling on excitatory synaptic trans-
mission in the PFC (Heng et al., 2011). Altogether, these data
suggest that developmentalmaturation of the PFC is accompanied
by a net downregulation of CB1R function.
In cortical areas, the CB1 receptor is known to be expressed in
pyramidal neurons and to a much greater extent in GABAergic
interneurons (Marsicano and Lutz, 1999; Hill et al., 2007), indi-
cating that CB1R has a greater modulatory role in GABA release.
In the neocortex, CB1R is expressed at high levels in a subpop-
ulation of cholecystokinin (CCK)-positive basket interneurons
and to a lower extent in calbindin-positive interneurons (Katona
et al., 1999; Marsicano and Lutz, 1999; Wedzony and Chocyk,
2009). Thus, these CB1-positive GABAergic interneuron popula-
tions are independent of the other well-characterized fast-spiking
parvalbumin-positive basket cells (Katona et al., 1999; Bodor et al.,
2005). Both types of basket cells mediate the perisomatic inhibi-
tion of pyramidal cells (Trettel and Levine, 2003) and are electri-
cally coupled to their own class (Hestrin and Galarreta, 2005), two
distinctive properties that makes them efﬁcient at synchronizing
the activity of pyramidal cells. However, CCK- and PV-positive
interneurons are differentially sensitive to cannabinoid-mediated
effects (Freund, 2003). PV-positive interneurons do not express
CB1R (Katona et al., 1999; Marsicano and Lutz, 1999; Bodor et al.,
2005; Eggan et al., 2010), and their inhibitory synapses with pyra-
midal cells are exempted from cannabinoid-mediated retrograde
signaling (Harkany et al., 2004; Galarreta et al., 2008).
In addition to the effects on GABAergic transmission, Fortin et
al. demonstrated in juvenile animals that only glutamatergic inputs
to layer 5 pyramidal neurons – themain output layer of the cortex –
are subjected to cannabinoid-mediated suppression of excitation
and not inhibition, while Layer 2/3 pyramidal neurons undergo
CB1-mediated suppression of excitation and inhibition, indicat-
ing that cannabinoids only control the glutamatergic input ontoL5
pyramidal cells but both the glutamatergic and GABAergic input
to L2/3 pyramidal cells (Trettel andLevine,2002; Fortin et al., 2004;
Fortin and Levine, 2007). This is consistent with the preferential
laminar distribution of CB1R and CCK-positive neurons/baskets
in Layer 2/3 (Marsicano and Lutz, 1999; Egertova and Elphick,
2000), while deeper layers show CB1R positive varicosities sug-
gestive of axons and terminals (Eggan et al., 2010). Therefore,
the developmental decrease in CB1R expression observed in our
study (Heng et al., 2011) would not only facilitate excitatory out-
put from the PFC during maturation, but would also increase
the cortico-cortical transmission of information received through
Layer 2/3.
CB1R SIGNALING, GABAergic INTERNEURONS, AND
CORTICAL NETWORK OSCILLATIONS: A WORKING MODEL
FOR PREFRONTAL DYSFUNCTION INDUCED BY
CANNABINOID EXPOSURE DURING ADOLESCENCE
Initial studies in the hippocampus indicated that acute admin-
istration of exogenous cannabinoids reduces cortical network
oscillations in the theta and gamma band (Robbe et al., 2006;
Hajos et al., 2008). Recently, Kucewicz et al. (2011) have demon-
strated that systemic administration of a potent CB1R agonist
(CP55,940) reduces gamma oscillations in the PFC as well as
hippocampal theta oscillations,which correlates with reduced per-
formance in a spatial working memory task. Notably, the reduced
gamma oscillations observed in schizophrenia are thought to be
an expression of reduced GABAergic interneuron transmission in
cortical circuits (Uhlhaas and Singer, 2006, 2010). Interestingly,
at the cellular level this decrease in gamma oscillations has been
linked to reduced function of PV-positive interneurons (Lodge
et al., 2009; Sohal et al., 2009; Volman et al., 2011) which lack
CB1R.Basedon the abundant expressionof CB1R inCCK-positive
GABAergic interneurons, it would suggest that a dysfunction of
this population is at least partially responsible for abnormal oscil-
lations caused by acute CB1R agonist administration. In support
of this hypothesis, CCK-positive and PV-positive interneurons are
anatomically and functionally coupled for sustaining fast oscilla-
tions in the hippocampus (Armstrong and Soltesz, 2012). Future
studies will need to determine the role of CB1R signaling in
the regulation of such interactions for maintaining gamma-range
synchronous activity in the frontal cortex.
From the developmental perspective, studies fromanimalmod-
els indicate that a remodeling of local inhibitory circuits within
the PFC during adolescence requires proper glutamatergic drive
from the ventral hippocampus (see review by Tseng et al., 2009).
In this regard, CB1Rs are also well positioned to exert presy-
naptic inhibition of excitatory synaptic transmission onto local
GABAergic circuits in the PFC. Thus, repeated exposure to THC
or excessive activation of CB1 receptors during adolescence could
signiﬁcantly reduce the level of glutamatergic drive needed for
the functional maturation of prefrontal GABAergic interneurons.
This would result in reduced inhibitory tone to cortical pyramidal
cells and consequently decreased synchronization of the prefrontal
network.
Based on the evidence presented above, cannabinoid sig-
naling acts in at least three distinct synapses within the PFC
to regulate both prefrontal input and output (Figure 1): (i)
www.frontiersin.org May 2012 | Volume 3 | Article 101 | 3
Caballero andTseng Adolescent cannabinoid exposure and prefrontal dysfunction
FIGURE 1 |Working model of prefrontal dysfunction induced by
cannabinoid exposure during adolescence. (A) During normal
development, the adolescent facilitation of glutamatergic transmission
onto prefrontal PV-positive interneurons is thought to determine the
maturation local GABAergic transmission in the PFC (Tseng et al., 2009).
(B) Based on the expression and function of CB1R in the cortex, the acute
effect of cannabinoids on prefrontal dysfunction could occur by
suppression of synaptic transmission at any of the following synapses
(black triangles): (i) CCK-positive interneuron → pyramidal neurons, (ii)
glutamatergic afferents → pyramidal neurons, and (iii) glutamatergic
afferents → PV-positive interneurons. Regarding the long-lasting effects of
adolescent exposure to cannabinoids, we hypothesize that
cannabinoid-induced (e.g., Δ9-THC) suppression of glutamatergic drive
onto PV-positive cells will prevent the normal maturation of these
interneurons. If such interneuronal activity does not become enhanced
during this transitional period, the control of PFC inhibition will be
profoundly reduced, resulting in a lack of synchrony in the PFC and
consequent impairment of cognitive functions.
GABAergic synapses of CCK-positive interneurons onto pyra-
midal neurons, (ii) glutamatergic afferents (e.g., thalamus, hip-
pocampus) onto pyramidal neurons, and (iii) glutamatergic affer-
ents onto PV-positive interneurons. While any of these synapses
could be the target of acute cannabinoid intoxication, only those
synapses that are developmentally regulated could explain the
long-lasting deﬁcits seen with early adolescent-onset cannabis
use/abuse. The data presently indicate that only the glutamater-
gic inputs (ii, iii), especially those contacting GABAergic PV-
positive interneurons, are developmentally regulated. Thus, ado-
lescent exposure to cannabis could disrupt the glutamatergic
facilitation of PV-positive interneuron function and underlie
the cognitive impairments seen in adulthood. It remains to be
determined whether CCK-positive interneurons follow dramatic
developmental changes similar to their PV-positive counterparts,
and if so, how would this play in the generation of prefrontal
synchrony.
All in all, these ﬁndings suggest that a downregulation of corti-
cal GABAergic function underlies the effects of CB1R stimulation
on cortical functioning. In turn, pyramidal neuron excitability will
be increased, resulting in an overall disinhibition of the PFC and
dysregulation of prefrontal-dependent processes. Overstimulation
of the CB1R over sensitive developmental periods could alter the
trajectory of any of the above-mentioned circuits leading to the
deﬁcits associated with schizoaffective disorders.
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